Tripotassium Citrate Monohydrate (TPC)

Jungbunzlauer is the worldwide leading supplier of Tripotassium Citrate Monohydrate (TPC) as an API with GMP quality and documentation, including Type II US DMF and CEP. TPC serves as potassium source in a wide range of nutritional and pharmaceutical applications. As an API, TPC is mainly used as urinary and systemic alkaliser to treat renal tubular acidosis (RTA, Butler-Albright-Lightwood-Syndrome). In addition, TPC prevents crystallisation of urates due to its citrate-based chelating properties and is used during kidney stone management therapy. Citrates react with stone forming cations to a soluble form and are subsequently excreted by the body. TPC is as well used as an API for electrolyte replenishment therapies in hypokalemia and its alkalising properties can be used to treat the symptoms of cystitis.

• Renal tubular acidosis/Kidney stone management
• Systemic alkaliser
• Hypokalemia/Electrolyte replenishment